Who is sponsoring NCT06101082?

NCT06101082 is sponsored by China Medical University, China.

What drugs are being tested in NCT06101082?

Interventions in NCT06101082: Intravenous infusion anti-HER2-CAR-T cell.

What condition does NCT06101082 study?

NCT06101082 studies Solid Tumor.

Is NCT06101082 still recruiting?

NCT06101082 is currently recruiting now. Last updated 6 March 2024.

Last reviewed 2024-03-06 · How we verify

NCT06101082

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors

Recruiting now Phase 1 Last updated 6 March 2024

What this trial tests

Phase 1 trial testing Intravenous infusion anti-HER2-CAR-T cell in Solid Tumor in 9 participants. Currently enrolling.

Timeline

16 January 2024

Primary endpoint
19 October 2026

19 October 2026

Quick facts

Lead sponsor	China Medical University, China
Phase	Phase 1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	16 January 2024
Primary completion	19 October 2026
Estimated completion	19 October 2026
Sites	1 location across China

Drugs / interventions tested

Intravenous infusion anti-HER2-CAR-T cell — full drug profile →

Conditions studied

Solid Tumor — all drugs for Solid Tumor →

Sponsor

China Medical University, China

Who can join

Adults 18 to 70, any sex, with Solid Tumor. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-center, open-label clinical study of anti-HER2-CAR-T cells for HER2+ patients with locally advanced and/or metastatic solid tumors. In this study, a single-dose regimen was designed, and the investigator had the discretion to decide whether the patient received more than once CAR T-cell therapy.This study intends to include HER2+ patients with locally advanced and/or metastatic solid tumors.They will take the anti-HER2-CAR-T cell transfusion after a screening period, mononuclear cell (PBMC) collection, bridging therapy if necessary, and lymphocyte clearance pretreatment period.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors.
Zhu L, Liu J, Li J, Wang N, et al · · 2025 · cited 3× · PMID 40469307 · DOI 10.3389/fimmu.2025.1514994
CAR-T cell therapy for pancreatic cancer: Translating emerging targets and dual-targeting strategies from solid tumors.
Shen S, Ruan Z, Jiang B, Qiu W, et al · · 2026 · PMID 42039159 · DOI 10.3389/fimmu.2026.1764452
Glutamate metabotropic receptor 4 in breast cancer: a potential and specific target for chimeric antigen receptor therapy.
Xu Y, Hayierhan A, Chen Z, Ma Y, et al · · 2025 · PMID 41573636 · DOI 10.3389/fonc.2025.1654977

Verify or expand the search:

Other recruiting trials for Solid Tumor

Currently open trials in the same condition.

NCT07489378 — NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rar · recruiting
NCT07487597 — Functionally Enhanced ALPP-Targeted Engineered T Cells in Advanced Solid Tumors · EARLY_PHASE1 · recruiting
NCT07382544 — Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss · Phase 1 · recruiting
NCT07466160 — A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
NCT07450560 — Research on Real-time Proton Therapy Guidance Through Monitoring Proton Range Using All-digital PET · active not recruiting

Other China Medical University, China trials

Trials by the same sponsor.

NCT07519837 — Study on the Pathogenesis and Reversal Strategies of Cancer Cachexia Based on Multi-Omics · NA · recruiting
NCT07388875 — Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC · Phase 2 · not yet recruiting
NCT07376499 — Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum a · Phase 2 · not yet recruiting
NCT07262840 — Health Behavior Change in High-Risk Colorectal Cancer Individuals · NA · recruiting
NCT07373964 — A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06101082 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by China Medical University, China
Last refreshed: 6 March 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06101082.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing